Former head of IDB group believes witness will corroborate allegations against Moti Ben-Moshe, who won control of IDB in January.
Labor strife at Israel Chemicals, Noble Energy CEO warns about delays, Borderfree expected to sell shares, Can-Fite Biopharma places $5m in equity with U.S. institutions and Tel Aviv shares end high.
Bank of Israel minutes show one dissenting voice, which is echoed by Hapoalim’s chief economist.
Attorney for Moti Ben-Moshe calls for probe into Dankner's last-minute attempt to block transfer of IDB.
News from Tamar, Teva, Fox and Adama, Tel Aviv shares dip.
The central bank chief, however, notes that she has record foreign currency reserves with which to intervene in the market.
IDB group's new controllers clash over both style and substance.
Announcement comes two days after Teva Pharmaceutical Industries sold back its stake in the drug firm and its flagship diabetes treatment.
Argentinean investor Eduardo Elsztain and Moti Ben-Moshe, his Israeli partner in IDB, just can’t get on with each other, but the bondholders look safe.
Executives from Warren Buffet’s Berkshire Hathaway meet with Shlomo Group, while some economists predict cut in base interest rates for March.